14.28 USD
+0.03 (+0.21%)
14.2505 USD
-0.03 (-0.21%)
We assign a fundamental rating of 4 out of 10 to FOLD. FOLD was compared to 530 industry peers in the Biotechnology industry. Both the profitability and the financial health of FOLD get a neutral evaluation. Nothing too spectacular is happening here. FOLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
FOLD had negative earnings in the past year.
FOLD had a positive operating cash flow in the past year.
In the past 5 years FOLD always reported negative net income.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
FOLD has a Return On Assets of -1.62%. This is amongst the best in the industry. FOLD outperforms 87.92% of its industry peers.
The Return On Equity of FOLD (-6.10%) is better than 89.06% of its industry peers.
The Return On Invested Capital of FOLD (4.07%) is better than 90.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROIC | 4.07% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of FOLD (5.77%) is better than 89.81% of its industry peers.
Looking at the Gross Margin, with a value of 89.77%, FOLD belongs to the top of the industry, outperforming 92.08% of the companies in the same industry.
FOLD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so FOLD is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FOLD has been increased compared to 5 years ago.
The debt/assets ratio for FOLD has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.04, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FOLD (1.04) is better than 63.58% of its industry peers.
FOLD has a debt to FCF ratio of 40.45. This is a negative value and a sign of low solvency as FOLD would need 40.45 years to pay back of all of its debts.
FOLD has a Debt to FCF ratio of 40.45. This is amongst the best in the industry. FOLD outperforms 89.81% of its industry peers.
FOLD has a Debt/Equity ratio of 1.70. This is a high value indicating a heavy dependency on external financing.
FOLD has a Debt to Equity ratio of 1.70. This is in the lower half of the industry: FOLD underperforms 77.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Altman-Z | 1.04 |
ROIC/WACC0.45
WACC9.14%
2.3 Liquidity
FOLD has a Current Ratio of 2.99. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD has a worse Current ratio (2.99) than 64.15% of its industry peers.
A Quick Ratio of 2.09 indicates that FOLD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.09, FOLD is doing worse than 72.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.18%, which is quite impressive.
Looking at the last year, FOLD shows a very strong growth in Revenue. The Revenue has grown by 21.28%.
The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 69.00% on average per year.
The Revenue is expected to grow by 19.14% on average over the next years. This is quite good.
EPS Next Y89.48%
EPS Next 2Y93.03%
EPS Next 3Y74.75%
EPS Next 5Y69%
Revenue Next Year19.4%
Revenue Next 2Y18.91%
Revenue Next 3Y18.81%
Revenue Next 5Y19.14%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
FOLD is valuated quite expensively with a Price/Forward Earnings ratio of 45.96.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 91.13% of the companies listed in the same industry.
FOLD is valuated expensively when we compare the Price/Forward Earnings ratio to 23.79, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.96 |
4.2 Price Multiples
89.43% of the companies in the same industry are more expensive than FOLD, based on the Enterprise Value to EBITDA ratio.
FOLD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FOLD is cheaper than 90.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 454.63 | ||
| EV/EBITDA | 105.68 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FOLD's earnings are expected to grow with 74.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y93.03%
EPS Next 3Y74.75%
5. Dividend
5.1 Amount
No dividends for FOLD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
14.28
+0.03 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.15%
Inst Owner Change0%
Ins Owners0.55%
Ins Owner Change-5.53%
Market Cap4.41B
Revenue(TTM)598.70M
Net Income(TTM)-14.06M
Analysts84.71
Price Target16.26 (13.87%)
Short Float %6.57%
Short Ratio2.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.12%
Min EPS beat(2)41.73%
Max EPS beat(2)52.51%
EPS beat(4)3
Avg EPS beat(4)76.91%
Min EPS beat(4)-26.06%
Max EPS beat(4)239.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.57%
Min Revenue beat(2)0.02%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.83%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.79%
Revenue beat(12)8
Avg Revenue beat(12)-0.1%
Revenue beat(16)9
Avg Revenue beat(16)-1.08%
PT rev (1m)-0.39%
PT rev (3m)0.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.44%
EPS NY rev (1m)0%
EPS NY rev (3m)62.02%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.96 | ||
| P/S | 7.36 | ||
| P/FCF | 454.63 | ||
| P/OCF | 339.54 | ||
| P/B | 19.12 | ||
| P/tB | 246.35 | ||
| EV/EBITDA | 105.68 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.31
Fwd EY2.18%
FCF(TTM)0.03
FCFY0.22%
OCF(TTM)0.04
OCFY0.29%
SpS1.94
BVpS0.75
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROCE | 5.15% | ||
| ROIC | 4.07% | ||
| ROICexc | 6.72% | ||
| ROICexgc | 14.09% | ||
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% | ||
| FCFM | 1.62% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Debt/EBITDA | 9.31 | ||
| Cap/Depr | 43.2% | ||
| Cap/Sales | 0.55% | ||
| Interest Coverage | 0.78 | ||
| Cash Conversion | 30.81% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z | 1.04 |
F-Score5
WACC9.14%
ROIC/WACC0.45
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y89.48%
EPS Next 2Y93.03%
EPS Next 3Y74.75%
EPS Next 5Y69%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
Revenue Next Year19.4%
Revenue Next 2Y18.91%
Revenue Next 3Y18.81%
Revenue Next 5Y19.14%
EBIT growth 1Y139.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.46%
EBIT Next 3Y89.53%
EBIT Next 5YN/A
FCF growth 1Y105.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y108.46%
OCF growth 3YN/A
OCF growth 5YN/A
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the fundamental rating for FOLD stock?
ChartMill assigns a fundamental rating of 4 / 10 to FOLD.
What is the valuation status for FOLD stock?
ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.
Can you provide the profitability details for AMICUS THERAPEUTICS INC?
AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.
What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?
The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 89.48% in the next year.